-
Most Recent
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
Is Arena Pharmaceuticals Any More Attractive Now That the Dust Is Settling?
Now that the Belviq approval-fueled craze has waned, investors can take a clearer look at Arena's numbers. They might be pleasantly surprised.
How to Pick the Best High-Yield Stocks in Big Pharma
Big Pharma is a great place to find yield, and health care is a sure-fire long-term bet. But rather than shake a stick at this sector, go ahead ... be picky.
CVS Caremark Tops Q2 Profit, Misses on Revenue
CVS Caremark posted increased second-quarter earnings that topped Wall Street forecasts, but missed on revenue, and raised its earnings outlook for the year.
Pharma’s Q2 Earnings Lesson: The Big Picture Looks Good
The promising signs coming out of pharma this quarter doesn't mean you can just pick a stock out of a hat -- but it does mean a few are worth picking.
Pfizer Tops Q2 Earnings Estimates
Pfizer posted second-quarter earnings that topped Wall Street estimates even as revenue declined compared to last year.
Should I Buy Merck? 3 Pros, 3 Cons
Pharma is a tough game, but thanks to its simultaneous continued R&D spending and cost-cutting, Merck has what it takes to win. Or does it?
3 High-Flying ETFs That Still Look Good
These three are among the best-performing funds so far this year and, comparatively speaking, look to hold their own at least in the short term.
Before You Assume the Worst for Vivus …
While there are many reasons to be pessimistic about the future of pharma stock Vivus, the research that has fueled its recent drop is not one of them.
5 Health Care Mutual Funds to Buy
As the baby boomers get creakier, health care is sure to flourish. These funds are a good way to get into this must-have sector.
Is It Time to Sell Abbott Labs?
Abbott Labs has been on a tear since October, but its technical strength is wearing thin, plus a few other factors stand to hamper this otherwise solid company.
Novartis Wins Approval for Breast Cancer Drug
The FDA has granted approval for Novartis' drug Afinitor to be used as a treatment for breast cancer after it showed promise in clinical trials.
Will Vivus Repeat Arena’s Non-Response?
Two days don't make or break a stock, but Vivus' response to Qsymia's approval is far from encouraging. The time to buy might be long past.
Divided, This Rally Cannot Stand!
The fact that Thursday's rally was restricted to just several sectors following a breakout means a slight correction could be due. Watch for new entry points.
7 Long-Term Demographic Trends to Play
Earnings and stock fundamentals are important, but don't miss the forest while looking at the trees. Here are the big-picture demographic trends to keep your eye on.
9 Biotech Buyout Players to Watch
The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next.
HGSI Holdout Proves Profitable — for Bagels
Joint pharmaceutical developers Human Genome and GlaxoSmithKline agreed to a sweetened $14.25/share offer for HGSI, cheering Rockville-area diners.
Swing for the Fences With These 5 Biotech Stocks
If you're prepared for the very high stakes and high risks of biotech investing, these five biotech stocks might be worth your while.
